2016 ACVIM Forum Research Abstract Program

Ten dogs with histologically confirmed OSA with no evidence of thoracic metastasis at diagnosis were treated with amputation followed by 4 doses of carboplatin chemotherapy (300 mg/m2 IV q 3 weeks). Fourteen days after chemotherapy was completed, TP was initiated at a dose of 2.75 mg/kg PO q 48 hours. Serum samples for VEGF and MMP-9, bloodwork to evaluate toxicity, screening for metastasis with thoracic radiographs, and quality-oflife (QOL) scores monitored via owner surveys were performed monthly. The Kaplan-Meier method was used to calculate OSAfree survival and overall survival (OS). A Friedman's test was used to compare VEGF and MMP values at baseline, pre-TP, and end of study. A Kruskal-Wallis test of repeated measures was used to compare platelet-corrected VEGF values at baseline, pre-TP, and end of study. P values of <0.1 were considered significant.